Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7013965 | 1.00 | HTR3B (0.48) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL829382 | 0.92 | HTR3B (0.50) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL3588169 | 0.91 | CYP2A6 (0.42) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL3586036 | 0.86 | HTR3B (0.48) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL11524815 | 0.81 | HTR3B (0.47) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL718791 | 0.79 | TSHR (0.40) | — | |
| SCHEMBL30739530 | 0.79 | TSHR (0.40) | — | |
| SCHEMBL829452 | 0.79 | TSHR (0.43) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL6854090 | 0.76 | PARP1 (0.56) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL7878541 | 0.76 | HPGD (0.51) | HTR3BADRA2AKCNE1ADRA2CCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2189443-B1 | TRICYCLIC AMIDE COMPOUND | RES FOUND ITSUU LAB (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-8232300-B2 | Tricyclic amide compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8143260-B2 | Tricyclic amine compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8067603-B2 | Opiod receptor-like receptors (ORL1); for treatment of chronic pain conditions, central nervous system disorders such as anxiety and stress disorders, depression, epilepsy, stroke, Alzheimer's disease, eating disorders, and drug abuse | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-11-29 | — | — | US | disclosed |
| US-8067603-B2 | Opiod receptor-like receptors (ORL1); for treatment of chronic pain conditions, central nervous system disorders such as anxiety and stress disorders, depression, epilepsy, stroke, Alzheimer's disease, eating disorders, and drug abuse | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-11-29 | — | — | US | disclosed |
| US-8067603-B2 | Opiod receptor-like receptors (ORL1); for treatment of chronic pain conditions, central nervous system disorders such as anxiety and stress disorders, depression, epilepsy, stroke, Alzheimer's disease, eating disorders, and drug abuse | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-11-29 | — | — | US | disclosed |
| US-20110288299-A1 | TRICYCLIC AMINE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2189440-A1 | TRICYCLIC AMINE COMPOUND | Research Foundation Itsuu Laboratory (JP) | 2010-05-26 | — | — | EP | disclosed |
| EP-2189443-A1 | TRICYCLIC AMIDE COMPOUND | Research Foundation Itsuu Laboratory (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20050070528-A1 | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS B.V. | 2005-03-31 | — | — | US | disclosed |
| WO-2005028466-A1 | BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-03-31 | — | — | WO | disclosed |
| US-6642247-B2 | Treting anxiety, stress, depression, trauma, Alzheimer's mediated memory loss, epilepsy, arterial blood pressure disorders, obesity, acute pain, chronic pain, Na+ excretion, control of water balance, and symptoms associated with drug | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-0963985-B1 | Di-or triaza-spiro(4,5)decane derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-12 | — | — | EP | disclosed |
| EP-0963985-A2 | Di-or triaza-spiro(4,5)decane derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-15 | — | — | EP | disclosed |
| US-4564698-A | Biologically-active tricyclic amines | AKZO N.V. (NL) | 1986-01-14 | — | — | US | disclosed |
| EP-0041293-B1 | BIOLOGICALLY-ACTIVE TRICYCLIC AMINES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AKZO N.V. (NL) | 1984-03-14 | — | — | EP | disclosed |
| WO-1981003490-A1 | BIOLOGICALLY-ACTIVE TRICYCLIC AMINES,METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AKZO NV (NL) | 1981-12-10 | — | — | WO | disclosed |
| EP-0041293-A1 | Biologically-active tricyclic amines, methods for their preparation and pharmaceutical compositions containing same | AKZO N.V. (NL) | 1981-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | NPY4R, NPY1R, OXER1 | HTR3B 624/4885ADRA2A 49/4885KCNE1 774/4885 |
| US-20050070528-A1 | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | OPRL1, ORMDL3, OGFRL1 | HTR3B 553/4885ADRA2A 254/4885KCNE1 1086/4885 |
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RXRA, RXRB, RXRG | HTR3B 924/4885ADRA2A 539/4885KCNE1 2853/4885 |
| US-20110288299-A1 | TRICYCLIC AMINE COMPOUND | RXRA, RXRB, NR2C2 | HTR3B 250/4885ADRA2A 130/4885KCNE1 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.